SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
SEC Accession No. 0001213900-24-009375
Filing Date
2024-02-02
Accepted
2024-02-02 09:50:12
Documents
1
Group Members
GUY LEVYSOLEUS CAPITAL GROUP, LLCSOLEUS CAPITAL, LLC

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO SCHEDULE 13G ea192414-13ga1soleus_jasper.htm SC 13G/A 154356
  Complete submission text file 0001213900-24-009375.txt   156181
Mailing Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065
Business Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065 6505491400
Jasper Therapeutics, Inc. (Subject) CIK: 0001788028 (see all company filings)

IRS No.: 842984849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-91228 | Film No.: 24589068
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 104 FIELD POINT ROAD 2ND FLOOR GREENWICH CT 06830
Business Address 104 FIELD POINT ROAD 2ND FLOOR GREENWICH CT 06830 4752083111
Soleus Capital Master Fund, L.P. (Filed by) CIK: 0001812275 (see all company filings)

IRS No.: 981413657 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SC 13G/A